Pfizer Anchors U.S. Gram-Positive Bacterial Infections Treatment Market Climb from USD 18.6 billion in 2026 and USD 33.9 billion by 2036 at 6.2% CAGR

ROCKVILLE, MARYLAND , August 27, 2026 — The gram positive bacterial infections treatment market is valued at USD 18.6 billion in 2026 and is forecast to reach USD 33.9 billion by 2036. The market is projected to expand at a compound annual growth rate (CAGR) of 6.2% over the 2026–2036 period. The market reached USD 17.5 billion in 2025. Absolute opportunity is expected at USD 15.3 billion by 2036.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15977

Key Findings

• Market size: USD 18.6 billion (2026) to USD 33.9 billion (2036).
• CAGR: 6.2% (2026–2036).
• Absolute opportunity: USD 15.3 billion by 2036.
• Leading therapeutic class: Beta-lactam Antibiotics at 39.0% share in 2026.
• Leading infection type: Skin & Soft Tissue Infections at 28.0% share in 2026.
• Leading end user: Hospitals at 44.0% share in 2026.
• Leading distribution channel: Hospital Pharmacies at 53.0% share in 2026.
• Leading drug class: Penicillin Derivatives at 36.0% share in 2026.

Growth Drivers

Demand is driven by hospital-managed serious infections, culture-guided treatment selection, formulary access for proven agents, stewardship-compatible prescribing, and outpatient and step-down treatment use.

Driver impact analysis (approximate contribution to CAGR):

• Hospital-managed serious infections: +1.8% (North America, Europe, East Asia; short term ≤2 years).
• Culture-guided treatment selection: +1.5% (global hospital systems; short term ≤2 years).
• Formulary access for proven agents: +1.2% (USA, Germany, UK, Canada; medium term 2–4 years).
• Stewardship-compatible prescribing: +1.0% (mature healthcare markets; medium term 2–4 years).
• Outpatient and step-down treatment use: +0.8% (USA, Japan, France; long term ≥4 years).

Opportunity impact analysis:

• Targeted use in severe infections: +0.9% (USA, Germany, Japan; medium term).
• Oral step-down pathways: +0.8% (USA, UK, Canada; medium term).
• Hospital pharmacy protocol support: +0.6% (mature hospital systems; long term).
• Specialist infectious disease review: +0.5% (North America and Europe; long term).

Segment Analysis by Product, Technology and Application

Therapeutic Class (Product)

• Beta-lactam Antibiotics: 39.0% share in 2026. Physicians use them across established Gram-positive treatment pathways; role is strongest where susceptibility results support narrow therapy. Glycopeptide antibiotics and oxazolidinones remain important when resistance or allergy requires a different approach.

Drug Class

• Penicillin Derivatives: 36.0% share in 2026. Protocol-led prescribing supports use in susceptible infections. Resistance and allergy considerations leave room for cephalosporins and vancomycin. Linezolid and daptomycin remain options in selected cases.

Infection Type (Application)

• Skin & Soft Tissue Infections: 28.0% share in 2026. Cellulitis and abscesses require fast decisions; wound infections add another treatment route. Many cases begin outside hospitals; complicated presentations can move into inpatient care.

End User

• Hospitals: 44.0% share in 2026. Serious Gram-positive infections often need culture review and intravenous therapy. Bacteremia, pneumonia, and complicated skin infections require longer care pathways. Stewardship teams influence formulary access.

Distribution Channel

• Hospital Pharmacies: 53.0% share in 2026. Control access through formulary review and inpatient dosing protocols.

Scope covers Staphylococcus species plus Streptococcus and Enterococcus species. Therapeutic classes include Beta-lactam Antibiotics, Glycopeptide Antibiotics, Oxazolidinones, and Lipopeptides. Infection types include Skin & Soft Tissue Infections, Respiratory Tract Infections, Bloodstream Infections, and Bone & Joint Infections.

Country-Level Growth Comparison

The country comparison spans 2.0 percentage points. The USA remains 0.3 percentage point above Germany; Germany remains 0.3 percentage point above Japan; Japan remains 0.4 percentage point above the UK; the UK remains 0.3 percentage point above Canada; Canada remains 0.4 percentage point above South Korea; South Korea remains 0.3 percentage point above France. Full report coverage includes North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa.

Competitive Landscape

Pfizer and Merck hold the strongest relevance in Gram-positive infection treatment. GSK and Sanofi add broader antibacterial and hospital-market depth. Melinta, Paratek and Basilea strengthen the field through focused antibiotic portfolios for serious infections. Roche, Baxter and Cumberland extend the provider base through hospital access, injectable therapy support and treatment availability across protocol-led care settings.

Key companies:

• Pfizer Inc.
• Merck & Co., Inc.
• GSK plc
• Sanofi SA
• Melinta Therapeutics LLC
• F. Hoffmann-La Roche Ltd.
• Paratek Pharmaceuticals, Inc.
• Baxter International Inc.
• Basilea Pharmaceutica Ltd.
• Cumberland Pharmaceuticals Inc.

Competitive analysis profiles the approved company set without adding company share.

Recent Developments

• Basilea Pharmaceutica Ltd. (May 20, 2025): Announced commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States.
• GSK plc (March 25, 2025): Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients 12 years of age and older.
• World Health Organization (October 13, 2025): Global antibiotic resistance surveillance report 2025.

Restraints

Growth is limited by resistance pressure and stewardship restrictions across antibiotics procurement. Supply reliability adds another constraint.

Restraint impact analysis (approximate contribution to CAGR):

• Resistance and susceptibility uncertainty: –1.2% (global; short term ≤2 years).
• Stewardship limits on broad use: –1.0% (USA, Germany, UK, Canada; short term ≤2 years).
• Generic price pressure: –0.7% (mature markets; medium term 2–4 years).
• Hospital supply and stocking risk: –0.5% (global hospital systems; long term ≥4 years).

Physicians may delay or change therapy when culture results do not support the initial choice. Hospitals are expected to restrict newer agents when older therapies remain suitable for susceptible infections. Established molecules can limit premium uptake unless a branded product solves a clear clinical access issue.

How to Choose

Procurement and R&D teams evaluating therapies for Gram-positive bacterial infections should apply the following criteria drawn from market dynamics:

1.     Confirm indication fit with culture results and susceptibility testing before broader use, as culture-guided selection supports demand.

2.     Prioritize agents with clear formulary access, stable supply, and protocol compatibility for hospital-administered therapies, where substitutions may disrupt compliance.

3.     Separate older protocol-based antibiotics from newer agents that require stronger clinical evidence matching hospital treatment gaps.

4.     Assess stewardship-compatible prescribing and training on infection type and pathogen fit to strengthen access discussions.

5.     Evaluate oral step-down pathways for carefully selected patients moving from inpatient to outpatient care where extended oral antibiotics fit stewardship rules.

6.     Verify reliable availability for injectable agents and hospital pharmacy protocol support to reduce access friction.

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/gram-positive-bacterial-infections-treatment-market

Report Scope

The report covers prescription antibacterial therapies used to treat infections caused by Gram-positive pathogens including Staphylococcus, Streptococcus, and Enterococcus species. Segmentation includes Therapeutic Class, Infection Type, End User, Distribution Channel, and Drug Class. Regions covered: North America; Latin America; Europe; East Asia; South Asia and Pacific; Middle East and Africa. Countries covered: USA; Germany; Japan; UK; Canada; South Korea; France. Forecast period: 2026 to 2036. The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews

Explore More Related Studies Published by Fact.MR Research

Artificial Intelligence in Hospital Operations Market- https://www.openpr.com/news/4597510/u-s-health-systems-and-microsoft-drive-ai-hospital-operations

Artificial Intelligence in Life Sciences Market- https://www.openpr.com/news/4597511/usa-ai-in-life-sciences-market-expands-as-iqvia-rolls-out-new

Medical Devices Electronic Data Interchange Market- https://www.openpr.com/news/4597525/opentext-scales-u-s-medical-device-edi-networks-as-market

Medical Device and Medtech Enterprise Resource Planning Market-  https://www.openpr.com/news/4597512/sap-se-takes-15-2-share-as-u-s-medical-device-medtech-erp

Medical and Pharmaceutical Static Sealing Solutions Market- https://www.openpr.com/news/4597513/trelleborg-supports-usa-medical-and-pharmaceutical-static

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

 - Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

 Flag: The quote attributed to analyst S.N. Jha is sourced directly from published commentary on the report page and requires standard PR media sign-off before official press wire dissemination.